/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Carisma Therapeutics Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$0.118 -0.4381(-43.81%) CARM at 04 Dec 2025 04:27 PM Biotechnology
Lowest Today 0.147
Highest Today 0.17
Today’s Open 0.158
Prev. Close 0.2739
52 Week High 1.27
52 Week Low 0.14
Day’s Range: Low 0.147 High 0.17
52-Week Range: Low 0.14 High 1.27
1 day return -
1 Week return -
1 month return -
3 month return -51.32
6 month return -11.64
1 year return -80.67
3 year return -96.49
5 year return -98.76
10 year return -

Institutional Holdings

Market Status

Strong Buy: 1

Buy: 0

Hold: 1

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 11.45 M

PB Ratio 114.0987

PE Ratio 0.0

Enterprise Value 10.98 M

Total Assets 30.46 M

Volume 15421470

Company Financials

Annual Revenue FY23:14919000 14.9M, FY22:40000000 40.0M, FY21:26544000 26.5M, FY20:11236000 11.2M, FY19:null 0.0M

Annual Profit FY23:6654000 6.7M, FY22:40000000 40.0M, FY21:26544000 26.5M, FY20:11236000 11.2M, FY19:null 0.0M

Annual Net worth FY23:-86879000 -86.9M, FY22:null 0.0M, FY21:-40774000 -40.8M, FY20:-28320000 -28.3M, FY19:-107500000 -107.5M

Quarterly Revenue Q2/2025:0 0.0M, Q1/2025:3729000 3.7M, Q3/2024:3385000 3.4M, Q2/2024:9197000 9.2M, Q1/2024:3397000 3.4M

Quarterly Profit Q2/2025:-356000 -0.4M, Q1/2025:3729000 3.7M, Q3/2024:3385000 3.4M, Q2/2024:8942000 8.9M, Q1/2024:1704000 1.7M

Quarterly Net worth Q2/2025:-9774000 -9.8M, Q1/2025:-9266000 -9.3M, Q3/2024:-12702000 -12.7M, Q2/2024:-11162000 -11.2M, Q1/2024:-18978000 -19.0M

Fund house & investment objective

Company Information Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidate includes CT-2401, which is in preclinical trail for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others. In addition, it develops in vivo CAR-M cell therapy to treat solid tumors, including hepatocellular carcinoma. Carisma Therapeutics, Inc. has collaboration and license agreement with ModernaTX, Inc. to address oncology gene therapies. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. Carisma Therapeutics, Inc. was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Organisation Biotechnology

Employees 46

Industry Biotechnology

CEO Mr. Steven Kelly

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow